Skip to main content

Table 3 Association analysis between five factors of PANSS and five SNPs of CDNF2 in patients with SZ

From: Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population

SNP Genotype Total PANSS Positive Negative Depression/anxiety Cognition Excitement/hostility
Stage 1 Stage 2 Stage 1 Stage 2 Stage 1 Stage 2 Stage 1 Stage 2 Stage 1 Stage 2 Stage 1 Stage 2
rs2577075 AA 80.46 ± 18.15 86.36 ± 8.49 20.22 ± 6.60 22.63 ± 5.53 17.02 ± 5.45 19.70 ± 3.39 14.39 ± 2.97 14.51 ± 2.28 16.73 ± 5.62 17.21 ± 3.93* 7.44 ± 3.53 6.93 ± 2.99
AG 81.24 ± 20.65 84.67 ± 11.44 20.49 ± 8.02 22.17 ± 5.95 17.76 ± 5.73 19.81 ± 3.25 13.70 ± 3.53 14.35 ± 2.75 16.67 ± 5.22 15.85 ± 3.71* 7.58 ± 4.03 7.22 ± 3.03
GG 84.45 ± 19.93 81.79 ± 10.21 19.83 ± 7.23 21. 09 ± 6.60 19.03 ± 5.53 18.74 ± 2.70 14.85 ± 3.39 13.35 ± 2.23 17.90 ± 5.20 14.87 ± 3.14* 7.33 ± 3.96 7.43 ± 3.13
rs2577074 AA 84.45 ± 19.93 83.16 ± 9.36 19.83 ± 7.23 22.14 ± 5.56 19.03 ± 5.53 19.30 ± 2.79 14.85 ± 3.39 14.11 ± 2.63 17.90 ± 5.20 15.95 ± 4.08 7.33 ± 3.96 6.50 ± 2.66
AG 81.24 ± 20.65 85.75 ± 10.34 20.49 ± 8.02 21.99 ± 6.14 17.76 ± 5.73 19.59 ± 3.34 13.70 ± 3.53 14.51 ± 2.38 16.67 ± 5.22 16.17 ± 3.75 7.58 ± 4.03 7.62 ± 3.05
GG 80.46 ± 18.15 84.48 ± 12.39 20.22 ± 6.60 22.54 ± 6.09 17.02 ± 5.45 20.17 ± 3.62 14.39 ± 2.97 13.63 ± 2.83 16.73 ± 5.62 16.21 ± 3.26 7.44 ± 3.53 7.04 ± 3.41
rs2249810 AA 82.33 ± 21.05 87.79 ± 14.62 18.87 ± 7.51 23.07 ± 6.58 18.80 ± 5.80 21.00 ± 4.28 15.03 ± 3.54 13.86 ± 3.03 17.70 ± 5.55 16.57 ± 3.82 6.80 ± 3.89 6.71 ± 3.43
AG 81.67 ± 20.87 85.00 ± 10.52 20.46 ± 8.01 21.97 ± 6.19 17.85 ± 5.84 19.60 ± 3.03 13.66 ± 3.57 14.38 ± 2.53 16.88 ± 5.35 16.29 ± 3.54 7.68 ± 4.05 7.32 ± 3.19
GG 81.77 ± 17.73 83.92 ± 9.27 20.74 ± 6.54 21.90 ± 5.56 17.42 ± 5.20 19.27 ± 3.12 14.42 ± 2.88 14.25 ± 2.48 16.74 ± 5.18 16.05 ± 3.92 7.57 ± 3.61 7.17 ± 2.83
rs2118343a CC 82.74 ± 19.47 85.00 ± 2.00 21.04 ± 7.30 19.33 ± 0.58 17.71 ± 5.57 20.00 ± 3.46 14.38 ± 3.23 13.33 ± 2.52 17.23 ± 5.47 18.33 ± 3.51 7.43 ± 3.93 8.00 ± 4.00
CG 80.05 ± 20.86 85.17 ± 10.43 19.03 ± 7.57 21.90 ± 5.72 17.90 ± 5.77 19.35 ± 3.29 13.63 ± 3.58 13.90 ± 2.41 16.63 ± 5.22 16.53 ± 3.45 7.68 ± 3.84 7.60 ± 3.21
GG 85.43 ± 15.64 84.50 ± 10.63 20.71 ± 8.28 22.32 ± 6.09 20.14 ± 5.18 19.68 ± 3.21 15.71 ± 3.20 14.40 ± 2.61 16.71 ± 4.23 15.86 ± 3.88 6.43 ± 3.82 6.96 ± 2.92
rs6506891 AA 81.07 ± 20.23 84.08 ± 9.28 18.48 ± 7.34 22.06 ± 5.66 18.55 ± 5.74 19.31 ± 3.11 15.14 ± 3.55 14.27 ± 2.46 17.55 ± 5.59 15.95 ± 3.97 6.41 ± 3.33 7.17 ± 2.81
AT 79.48 ± 20.69 84.84 ± 10.51 19.08 ± 7.65 21.93 ± 6.14 17.69 ± 5.61 19.63 ± 3.01 13.29 ± 3.56 14.34 ± 2.53 16.31 ± 4.84 16.20 ± 3.58 7.85 ± 3.92 7.32 ± 3.17
TT 82.94 ± 19.02 86.87 ± 14.53 21.39 ± 7.24 23.20 ± 6.36 17.68 ± 5.60 20.67 ± 4.32 14.32 ± 3.15 13.67 ± 3.02 17.10 ± 5.49 16.40 ± 3.74 7.52 ± 3.86 6.53 ± 3.38
  1. P < 0.05, compared with each other genotype, LSD tests
  2. aCombine stage 1 and 2 samples: rs2118343 genotypes were significantly associated with negative factor scores